scispace - formally typeset
Search or ask a question
Topic

Psychotropic drug

About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.


Papers
More filters
Book ChapterDOI
01 Jan 1984
TL;DR: It is important to search for valid treatment alternatives to lithium and, if lithium treatment is indicated, to administer the treatment in the most effective way, possibly in connection with other treatment modalities.
Abstract: Long-term lithium treatment effectively prevents manic and depressive relapses in many patients with affective disorders. Recent comprehensive reviews have summarized the evidence for efficacy in bipolar (Schou, 1979a) as well as in unipolar patients (Schou, 1979b). However, lithium treatment is not effective in all patients with affective disorders and the treatment is not without inconveniences and at times even hazards. It is therefore important both to search for valid treatment alternatives to lithium and, if lithium treatment is indicated, to administer the treatment in the most effective way, possibly in connection with other treatment modalities.
Book ChapterDOI
01 Jan 1981
TL;DR: The large number of binding studies carried out in recent years rather reflects the fact that there is a multitude of additional drug binding sites, such as metabolic and transport sites, as well as a variety of non-specific sites.
Abstract: Most pharmacological actions are the result of binding of drug molecules to specific receptors. However, only in a few instances are these receptors known entities which lend themselves to investigation. Thus, the large number of binding studies carried out in recent years rather reflects the fact that there is a multitude of additional drug binding sites, such as metabolic and transport sites, as well as a variety of non-specific sites. The latter are also called ‘silent receptors’ or ‘sites of loss’ since their occupation does not result in pharmacological actions. However, this kind of binding is believed to be a major determinant of pharmacokinetics which again modifies pharmacodynamics.
Journal ArticleDOI
TL;DR: The aim was to minimise non-recommended drug use as defined by the guidelines of the Swedish Medical Product Agency (SMPA).
Abstract: Intervention NHs were allocated to an experimental intervention group (15 NHs, 626 residents) or a control group (18 NHs, 1228 residents). The experimental intervention involved 1 visit each month by a pharmacist who organised team meetings of the NH physician and nursing personnel to discuss drug use in individual residents. The aim was to minimise non-recommended drug use as defined by the guidelines of the Swedish Medical Product Agency (SMPA). Control group NHs received no special efforts to influence drug prescribing except the SMPA guidelines which were distributed to all physicians at the start of the intervention.
Patent
28 Oct 2013
TL;DR: In this article, the authors present methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia.
Abstract: The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b.

Network Information
Related Topics (5)
Schizophrenia
38.2K papers, 1.6M citations
86% related
Anxiety disorder
17.6K papers, 1.3M citations
86% related
Comorbidity
26.8K papers, 1.4M citations
82% related
Anxiety
141.1K papers, 4.7M citations
81% related
Mental health
183.7K papers, 4.3M citations
81% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202332
202268
202175
202058
201960
201876